BioWorld

March 22, 2004

View Archived Issues

Critical Therapeutics Files For Estimated $103.5M IPO

Read More

Makeup Of Bush's Bioethics Committee Comes Under Fire

Read More

Chiron's Tezacitabine Scrapped After Phase II Trial Misses Goal

Read More

Other News To Note

Read More

$100M In Private Funds Expected To Expand Neurogen's Portfolio

Neurogen Corp.'s stock rose on Friday, following news that the company entered an agreement to privately sell $100 million worth of common shares. (BioWorld Today) Read More